Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus EPANOVA.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution